Everest Medicines Ltd. has announced positive results from its ongoing Phase 1b/2a clinical trial for EVER001, a next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, aimed at treating primary membranous nephropathy (pMN) and other autoimmune renal diseases. The results were presented in a focused oral session at the 62nd Congress of the European Renal Association (ERA 2025). EVER001 was found to be generally safe and well tolerated, with no clinically significant adverse events typically linked to covalent irreversible BTK inhibitors, such as bleeding or severe liver function impairment. This trial marks a significant step as there is currently no globally approved drug for pMN, and EVER001 has the potential to provide new treatment options for over 10 million patients worldwide. The company plans to continue the global clinical development of EVER001.